Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2017

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Lapatinib and RAD-001

"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."

Trial Locations (1)

66160

University of Kansas Medical Centner, Kansas City

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Kansas Medical Center

OTHER